Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.55 |
| ▸ | CHUK | O15111 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259609 | 0.90 | ALDH1A1 (0.62) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL18343125 | 0.89 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL5928817 | 0.83 | TSHR (0.80) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL277775 | 0.82 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL277650 | 0.82 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL259608 | 0.82 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL259597 | 0.81 | SMN1; SMN2 (0.73) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL7314121 | 0.78 | MEN1 (0.68) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL11246385 | 0.77 | MEN1 (1.00) | ALDH1A1KMT2AMEN1MAPTKDM4E | |
| SCHEMBL259618 | 0.77 | MEN1 (0.67) | ALDH1A1KMT2AMEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| CN-108349910-A | glucose uptake inhibitor | 卡德门企业有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210331-A1 | TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | ALDH1A1 4428/4885KMT2A 1722/4885MEN1 3330/4885 |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | ALDH1A1 539/4885KMT2A 1860/4885MEN1 2827/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | ALDH1A1 590/4885KMT2A 1865/4885MEN1 3055/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | ALDH1A1 4428/4885KMT2A 1722/4885MEN1 3330/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | ALDH1A1 4428/4885KMT2A 1722/4885MEN1 3330/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | ALDH1A1 1239/4885KMT2A 2294/4885MEN1 2336/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | ALDH1A1 539/4885KMT2A 1860/4885MEN1 2827/4885 |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | SLC5A1, SLC2A1, SLC2A4 | ALDH1A1 776/4885KMT2A 1811/4885MEN1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.